Extension of Timetable in relation to Placing
Oxford BioDynamics Plc has extended the timetable for the settlement of a £250,000 outstanding payment from Vulpes Investment Management, a related party, to October 30, 2026, as part of a previously announced £9.15 million placing. This extension, agreed upon by the company and its advisors, is considered fair and reasonable by the directors not involved in the placing and is not expected to impact the company's financial position or prospects. Vulpes, through its associated funds, is a significant shareholder, holding 6.46% of the company's issued share capital, with a non-executive director having an interest in these holdings.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of £0.001 per Placing Share (the “Placing”). The Placing was approved at a shareholder meeting on 26 August 2026 and the Placing Shares were admitted to trading on AIM on 27 August 2026.
The proceeds of the Placing were received by the Company at the time of Admission, in accordance with the terms of the Placing Agreement, save for £250,000 which has yet to be received from Vulpes Investment Management (“Vulpes”). As announced on 10 August 2026, funds managed by Vulpes, including Vulpes Life Sciences Fund, had agreed to subscribe for 500,000,000 Placing Shares for a total consideration of £500,000. To date £250,000 has been received, with a further £250,000 yet to be paid. Vulpes, who have been a longstanding and supportive investor in the Company for several years, have informed the Company that they will settle the balance of their contractual commitment under the Placing shortly.
Accordingly, the Company, Singer Capital Markets and Merlin Partners LLP, who are parties to the Placing Agreement, have, at the request of Vulpes, today agreed to extend the time period under the Placing Agreement for payment to 30 October 2026.
The Company confirms that it is has received the entire net proceeds of the Placing, save for the £250,000 referred to above, and that this matter will not impact upon the Company’s financial position or prospects. The Company expects to receive the remaining funds on or before 30 October 2026.
Related Party Transaction
Martin Diggle, a non-executive director of the Company, is the co-founder of Vulpes and is Chairman and a director of the Vulpes Life Sciences Fund. Excluding the 250,000,000 Placing Shares that have not yet been paid for in accordance with the terms of the Placing, Vulpes has an interest over 868,542,844 Ordinary Shares, representing 6.46% of the Company’s issued share capital as at the date of this announcement.
The agreement with Vulpes pursuant to which the parties to the Placing Agreement have agreed to extend the time period under the terms of the Placing Agreement is considered to be a 'related party' transaction pursuant to Rule 13 of the AIM Rules.
The Directors of the Company who did not participate in the Placing (being Dr David Holbrook and Peter Presland), having consulted with the Company's nominated adviser, Singer Capital Markets Advisory, consider the amendment to the terms of the Placing Agreement to be fair and reasonable insofar as Shareholders are concerned.
Martin Diggle’s interests in the Company are amended from the statement made on 10 August 2026 and are as set out below:
| Director/PDMR | Existing beneficial shareholding | Placing Shares | Beneficial shareholding following the Placing | Shareholding as a percentage of the Enlarged Ordinary Share Capital |
|---|---|---|---|---|
| Martin Diggle 1 | 618,542,844 | 250,000,000 | 868,542,844 | 6.46% |
1 Martin Diggle’s beneficial holding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Martin Diggle | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification / Amendment | Amendment to disclosure made on 26 August 2026 | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.001 each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information | N/A | ||||
| e) | Date of the transaction | 26 August 2026 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (AIMX) |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.